Implementing Human iPSC-derived Cells in Early Safety Assessment and Disease Modeling

Presented by: Fujifilm Cellular Dynamics, Inc. and Nanion Technologies GmbH

Speakers: T.K. Feaster, PhD, Product Manager, Fujifilm Cellular Dynamics, Inc. and Sonja Stoelzle-Feix, PhD, Director, Scientific Affairs, Nanion Technologies GmbH

Part I: 12:30 – 12:45 pm
Dr. T.K. Feaster will discuss the predictive power of human iPSC-derived cells for in vitro toxicity testing. He will highlight toxicology, drug screening, and disease models. Demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.

Part II: 12:50 – 1:20 pm
Dr. Sonja Stoelzle-Feix will discuss the effects of “CiPA drugs” on excitation-contraction coupling in iCell Cardiomyocytes2. She will describe the evaluation of the proarrhythmic potential of 23 blinded drugs on hiPSC-CMs using iCell Cardiomyocytes2 and the Nanion CardioExcyte 96 at different sites. Ion channel data and myocyte behavior will be discussed and aligned.

(Oct 2, 2018)

Utilizing Novel Functional Assays with High-definition Multielectrode Arrays to Uncover Phenotypic Differences in Neurons Harboring Single-nucleotide Disease Mutations

Kile Mangan, Cellular Dynamics International at The Biophysical Society 2018 Annual Meeting, Exhibitor Presentation, San Francisco, CA

Dr. Kile Mangan from Cellular Dynamics International will follow with a talk on utilizing novel functional assays with high-definition multielectrode arrays (HD-MEAs: MaxWell Biosystems) to uncover phenotypic differences in neurons harboring single-nucleotide disease mutations (alpha synuclein A53T Parkinson’s Disease) or in normal control following pharmacological perturbation.

(Feb 18, 2018)

Human iPSC-derived Midbrain Dopaminergic Neurons for Parkinson’s Disease Modeling and Cell Therapy

Coby Carlson & Chris McMahon, Cellular Dynamics International at the ISSCR 2017 Innovation Showcase in Boston, MA

Parkinson’s disease (PD) affects approximately 1% of people over the age of 65 and is the second most common neurodegenerative disorder after Alzheimer’s disease. The advent of induced pluripotent stem cell (iPSC) technology now grants us access to previously unattainable cell types in the human brain. In this presentation, we will discuss how stem cells are being used not only to study PD in the lab, but also to develop treatments for PD using cells as therapies. Specifically, we have created an isogenic disease model for PD using human iPSC-derived midbrain dopaminergic neurons and have developed in vitro assays for comparative analysis of mitochondrial bioenergetics, calcium handling, and network-level electrophysiology. In the regenerative medicine space, we are actively manufacturing cGMP HLA “superdonor” iPSC lines for universal utility and will provide an update on our progress in developing iPSC-derived cellular therapies, including our program to treat PD by engrafting human midbrain dopaminergic neurons.

(Jun 15, 2017)

New Cellular Dynamics Product Portfolio Introduced at SLAS 2016

Chris Parker, Cellular Dynamics International at SLAS2016 in San Diego, Presented by LabTube

Part of the “LabTube Meets…” series, Chris Parker, Executive VP and Chief Business Officer of Cellular Dynamics describes the recently launched MyCell Disease & Diversity Products. Chris was interviewed at SLAS 2016 in San Diego.

(Jan 25, 2016)

Driving Diabetes-related Research through Pathway Dissection of Human iPSC-derived Cell Models

Tutorial presented by Nicolas Pierre, Cisbio Bioassays and Coby Carlson, Cellular Dynamics International at SLAS2016 in San Diego

This tutorial details how the combination of iPSC-derived cell types from Cellular Dynamics International (CDI) have been used with HTRF assays from Cisbio to dissect various cell signaling events and to quantify biomarker production or cytokine release, particularly around cell stress and inflammation.

(Jan 25, 2016)

PharmaTelevision News Review Interviews Chris Parker, Executive Vice President, Cellular Dynamics

Adrian Dawkes interviews Chris Parker at the 2015 World Stem Cells and Regenerative Medicine Congress in London

Chris Parker describes the technological origins, current product and service offerings and future applications of Cellular Dynamics induced pluripotent stem cell technology in the fields of drug discovery, toxicology and the development of therapeutic applications.

(May 20, 2015)

Using Patient Specific iPSC-Cardiomyocytes for Disease Modeling

Ulrich Broeckel, MD, Medical College of Wisconsin
Presented at the SLAS 2015

Left ventricular hypertrophy (LVH) is a common, complex, and independent risk factor for cardiovascular disease. This tutorial covers translating LVH from the clinic into the discovery laboratory through generating populations of patient-specific iPSC-cardiomyocytes, identifying unique pathophysiological markers, and implementing novel high-throughput screening methodologies. Ultimately, discovery and screening approaches that utilize clinical cohorts will generate more effective therapeutic approaches as they can account for population variances in both disease manifestation and intervention response.

(Feb 10, 2015)

Integrating Target-based and Phenotypic Screening Strategies with Human Cardiomyocytes

Blake Anson, PhD, Cellular Dynamics International
Presented at the SLAS 2015

This tutorial describes the use of iPSC Technology and Clinical Populations to Identify New Approaches for Treating Cardiac Hypertrophy

(Feb 10, 2015)

Cellular Dynamics Product Tour

Emile Nuwaysir, PhD, Cellular Dynamics International

Emile Nuwaysir, Chief Operating Officer of Cellular Dynamics International, introduces the range of iCell® Products available from CDI.

(Nov 1, 2013)

Neurite Outgrowth

Time-Lapse of Neurite Outgrowth of Plated iCell® Neurons

(Jan 9, 2013)

Neurite outgrowth of plated iCell Neurons over a twenty eight day period in Cellular Dynamics Maintenance Medium

Capillary-like Network Formation of iCell® Endothelial Cells in PEG Hydrogel

Courtesy of Michael Schwartz, PhD, University of Wisconsin

Time-lapse video images illustrating 3D capillary-like network formation for iCell® Endothelial Cells encapsulated in a synthetic polyethylene glycol (PEG) hydrogel. Images shown for time points recorded over days 2-3 in culture. The PEG hydrogel was formed with protease-degradable crosslinks and a pendant adhesion peptide to promote cellular remodeling, and grown in standard CDI-recommended media & supplement.

(Jan 9, 2013)

Functional Characterization of iCell® Neurons

iCell Neurons from Cellular Dynamics are characterized for their response to GABA or GABAzine as measured on an Axion Biosystems MEA platform. The cells exhibit the appropriate neuronal response to neuroactive compounds.

(Jan 9, 2013)

Screen Shot 2015-03-17 at 5.10.40 PMFit for Purpose: Temporal Bioenergetic and Transcriptomic Characterization of iCell Cardiomyocytes over Extended Culture Periods

Yvonne Will, PhD, Pfizer, Inc.
Presented at the Cellular Dynamics Workshop at SOT 2012

(May 13, 2012)

Screen Shot 2015-03-17 at 5.11.29 PMTKI-mediated Cardiotoxicity: iCell Cardiomyocytes as a Tool to Decipher Kinase Inhibitor Linked Toxicities

Jennifer Cohen, Takeda California, Inc.
Presented at the Cellular Dynamics Workshop at SOT 2012

(May 13, 2012)

View the Roche video, Arrhythmia Prediction Using iCell® Cardiomyocytes and the xCELLigence RTCA Cardio SystemScreen Shot 2015-03-17 at 5.24.43 PM

Ion channel block is detected as irregular contractile activity in the hCAR Assay. iCell Cardiomyocytes were plated as a confluent monolayer and exposed to 0.03 mM of the hERG channel blocking agent, E-4031. The video shows the rhythmic contractile activity of the cardiomyocytes under control conditions (pre-drug) and the arrhythmic activity following drug application (E-4031 0.03 mM). Courtesy of Hoffmann-La Roche

Electrophysiology of hiPSC-derived Cardiomyocytes

From: The Podcast Series for AJP – Heart and Circulatory Physiology

The discovery of induced pluripotent stem (iPS) cells has allowed researchers to generate human cardiomyocytes from patients. Why is this important? Human iPS cells are useful for studying normal and diseased human cardiomyocytes and for discovering new drug therapies to treat cardiovascular disease. Until now, methods for generating cardiomyocytes from human iPS or ES cells were inconsistent and often unreliable. The recent article by Ma et al presents a new method to obtain a large quantity of cultured cardiac myocytes using embryoid body formation and blasticidin selection techniques resulting in more than 98% purity from human iPS cell lines. Associate Editor Junichi Sadoshima talks with authors Craig January (University of Wisconsin – Madison) and Brad Swanson (Cellular Dynamics International), along with leading expert Diego Fraidenraich (University of Medicine and Dentistry, New Jersey), about this groundbreaking research and its many potential applications.

Stem Cells from Blood Cells

Jeff Angileri, WMSN Fox 47, Madison, WI

News coverage from WMSN Fox 47 in Madison, WI of Cellular Dynamics stem cell technology and applications of adult-derived pluripotent stem cells in drug and therapeutic development.

(Oct 26, 2011)

Training Video: Handling iCell Cardiomyocytes

This training video shows the proper techniques for storing, thawing, seeding, plating and maintaining iCell® Cardiomyocytes for use in your intended assays. Please contact Cellular Dynamics Technical Support for additional questions about these cells, and their proper handling and use in your assay application.

(Oct 21, 2011)